Vertex Pharmaceuticals (LTS:0QZU) Total Liabilities : $6,384 Mil (As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Vertex Pharmaceuticals Total Liabilities?

Vertex Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2025 was $6,384 Mil.

Vertex Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2024 ($6,609.30 Mil) to Dec. 2024 ($6,123.60 Mil) but then increased from Dec. 2024 ($6,123.60 Mil) to Mar. 2025 ($6,384.20 Mil).

Vertex Pharmaceuticals's annual Total Liabilities increased from Dec. 2022 ($4,238.20 Mil) to Dec. 2023 ($5,149.80 Mil) and increased from Dec. 2023 ($5,149.80 Mil) to Dec. 2024 ($6,123.60 Mil).

Vertex Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Vertex Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Total Liabilities Chart

Vertex Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

3,065.00

3,332.50

4,238.20

5,149.80

6,123.60

Vertex Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															5,370.80	5,357.40	6,609.30	6,123.60	6,384.20

Vertex Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Vertex Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3564.6	+	(1657.2	+	203.2
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	698.6)
	=	6,124

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	22533.2	-	16409.6
	=	6,124

Vertex Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3783.2	+	(1649.1	+	951.9
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	698.6)
	=	6,384

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	22880.5	-	16496.3
	=	6,384

Vertex Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Vertex Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (LTS:0QZU) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

VRTX:USA VRTX:Mexico 1VRTX:Italy VX1:Germany VX1:Germany VX1:Germany VX1:Germany VRTX34:Brazil VRTX:Austria

Address

50 Northern Avenue, Boston, MA, USA, 02210

Website

https://www.vrtx.com

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals Headlines

No Headlines